Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Skye Bioscience’s Next Steps After Glaucoma Trial Disappointment
Skye Bioscience’s phase 2a clinical trial of its SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has failed to meet its primary endpoint for lowering intraocular pressure (IOP). Consequently, the company announced its decision…
Melt Pharmaceuticals Launches MELT-300 Phase 3 Program
Melt Pharmaceuticals has completed the dosing of its first patient in its phase 3 program for MELT-300, marking a crucial step in evaluating the safety and efficacy of this pioneering product. MELT-300 is a non-intravenous, non-opioid tablet comprising fixed doses…
Rayner Announces 3 Key Appointments to Management Board
Rayner has made three key additions to its management board to foster continued growth and development within the organization. James Crutchlow has been appointed as Chief Commercial Officer, Rob Nadler as Chief Growth Officer, and Chris Willis as Chief Marketing…
Italy Probes Pharma Giants for Market Manipulation
Italy’s antitrust regulator has initiated a probe into several pharmaceutical giants, including Novartis, amid suspicions of anti-competitive practices in the sale of a drug targeting eye conditions. The investigation follows concerns regarding potential market restrictions and delayed product launch of…
BIOPHTA Secures €6.5M to Advance Eye Disease Therapy
BIOPHTA, a preclinical biotech company, has successfully closed a Seed round, raising €6.5 million to advance its pioneering technology into clinical development for the treatment of glaucoma and macular edema. This significant funding injection, led by prominent European venture capital…
Novel Eyeglass Lens Tech Offers Relief for Migraine Patients
This spring, individuals grappling with migraines find relieve with a novel solution for managing light sensitivity, thanks to new eyeglass lens technology developed by a physician-scientist at the University of Utah John A. Moran Eye Center. The Impact of Migraine…
Funding Boost for LambdaVision’s Artificial Retina
LambdaVision, a pioneering company dedicated to developing a protein-based artificial retina aimed at restoring sight lost to retinal degenerative diseases, announced the successful first closing of its seed round to advance its artificial retina development. The funding injection will fuel…
Quantel Medical Launches POCKET III
Quantel Medical, a division of Lumibird Medical, has unveiled its latest innovation with the launch of the POCKET III handheld pachymeter. This compact device, according to Quantel, sets a new standard as the lightest connected handheld pachymeter on the market,…
Zeiss Introduces Upgraded Cirrus 6000 OCT
Zeiss Medical Technology has introduced a series of enhancements to the Cirrus 6000, promising a more streamlined and data-centric workflow for ophthalmologists. This update boasts the largest OCT reference database in the US market and fortified cybersecurity features. With recent…
AAO’s Tool for Enhanced IOL Cataract Surgery
The U.S. Food and Drug Administration (FDA) has qualified the Assessment of IntraOcular Lens Implant Symptoms (AIOLIS), developed by the American Academy of Ophthalmology (AAO), as a Medical Device Development Tool (MDDT). This designation empowers medical device sponsors to employ…